Rising, Anna
- Institutionen för husdjurens biovetenskaper, Sveriges lantbruksuniversitet
- Karolinska institutet
Sammanfattning
AimIn acute respiratory distress syndrome (ARDS) damaged alveolar epithelium, leakage of plasma proteins into the alveolar space and inactivation of pulmonary surfactant lead to respiratory dysfunction. Lung function could potentially be restored with exogenous surfactant therapy, but clinical trials have so far been disappointing. These negative results may be explained by inactivation and/or too low doses of the administered surfactant. Surfactant based on a recombinant surfactant protein C analogue (rSP-C33Leu) is easy to produce and in this study we compared its effects on lung function and inflammation with a commercial surfactant preparation in an adult rabbit model of ARDS.MethodsARDS was induced in adult New Zealand rabbits by mild lung-lavages followed by injurious ventilation (V-T 20m/kg body weight) until P/F ratio
Nyckelord
ARDS model; Surfactant protein analogues; Synthetic pulmonary surfactant; Lung function
Publicerad i
Respiratory Research
2019, volym: 20, nummer: 1, artikelnummer: 245
Utgivare: BMC
SLU författare
UKÄ forskningsämne
Lungmedicin och allergi
Publikationens identifierare
- DOI: https://doi.org/10.1186/s12931-019-1220-x
Permanent länk till denna sida (URI)
https://res.slu.se/id/publ/102807